Empowering Scientists for the Benefit of Human Health


The Leader in Cell Line Development

Selexis is the global leader in mammalian cell line development that leverages best-in-class protein expression technologies and modular workflows to create highly specialized solutions that enable the bio-pharmaceutical industry to streamline the drug discovery through development continuum and rapidly commercialize innovative biologic-based medicines and vaccines against diseases of high unmet need such as cancer, autoimmune and inflammatory diseases, infectious diseases, blood, metabolic and genetic disorders as well as dermatology and opthalamic (eye) diseases.

Connect with us. From ubiquitous immunoglobulin-based drugs such as monoclonal and bi-specific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice.

Protein Expression with the SUREtechnology PLATFORM

Selexis Genetic Elements Technologies Icon

Advanced Gene Technologies

Selexis SGE® (Selexis Genetic Elements)

SUREtech Vectors™

SUREfection Procedures™

SUREvariant Screening™

Selexis CHO-M Cell Line Icon

Proprietary CHO-M Cell Line

CHO-M Cell Line™ (CHO-K1)

SURE CHO-Mplus Libraries™

Selexis Media and Feed Strategies-02

Media and Feed Strategies

SUREfeed Strategy™

Off-the-Shelf Media

Off-the-Shelf Feed

Selexis Clonality Icon

Product and Cell Line Analytics/ Characterization



Product Quality

News, Events and Blog

3 min read

Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

Geneva, Switzerland, and Paris, France, January 19, 2022Selexis SA, a JSR Life Sciences company, and Inotrem SA, an...

Read More

BioPharma Expo (Interphex Japan), Japan | December 8 – 10, 2021
– Attending

Read More
2 min read

Cell Line Development: It’s More Complicated Than You Think

Just as it is well understood that silicon chips must be made in sophisticated factories with the appropriate...

Read More

Bioprocessing 4.0


"In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, we must apply Bioprocessing 4.0,"

Selexis CHO cells high expressing mAB bispecific antibody



Our global partners are utilizing Selexis protein expression technologies and proprietary CHO cell line to advance a pipeline of more than 140 drug products in clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.



Connect with Us